

29 October 2015

ASX RELEASE

Cleansing Notice – Share purchase plan


Under ASIC Class Order 09/425 (**CO 09/425**), Prescient Therapeutics Limited (ASX: PTX) (**Prescient**) gives notice that:

- 1 Prescient will make offers to issue ordinary shares under a share purchase plan (**SPP**) without disclosure under part 6D.2 *Corporations Act 2001* (Cth) (**Corporations Act**);
- 2 this notice is given under CO 09/425 and in particular, paragraph 7(f)(ii) of CO 09/425 which requires that Prescient gives this notice to ASX within the 24 hour period before the SPP offer;
- 3 at the date of this notice, Prescient has complied with:
 - (a) the provisions of chapter 2M Corporations Act as they apply to Prescient; and
 - (b) section 674 Corporations Act; and
- 4 at the date of this notice, there is no 'excluded information' (within the meaning of sections 708A(7) and 708A(8) Corporations Act, as if this notice were a notice under section 708A(5)(e) Corporations Act).

For and on behalf of the board of Prescient.



Steve Engle
Chairman
Prescient Therapeutics Limited



About Prescient Therapeutics Limited (PTX)

PTX is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

Lead drug candidate PTX-200 inhibits an important tumor survival pathway known as AKT, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukaemia. This highly promising compound is now the focus of two current clinical trials. The first is a Phase 1b/2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York. A Phase 1b/2 trial of the compound in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at Florida's Lee Moffitt Cancer Center. These trials are funded in part by grants from the U.S. National Cancer Institute. In addition, PTX is planning a Phase 1b/2 trial evaluating PTX-200 as a new therapy for acute myeloid leukemia.

PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors.

PTX has licensed access to its Co-X-Gene™ platform technology to French biotechnology company Transgene for use in two immunotherapeutic products.

Further Inquiries:

Steven Engle
Chairman
+1 858 922 7768 (US)

Paul Hopper
Executive Director
+61 406 671 515

Rudi Michaelson
Monsoon Communications
+61 (0) 3 9620 3333